

August 23, 2019

Whom It May Concern

Company: KYORIN Holdings, Inc.  
Representative: Yutaka Ogihara  
Representative Director, President  
(Security Code: 4569, TSE 1st Sec.)  
Contact: Yoshinori Tanifuji  
Director, Management Strategy &  
Planning Division Corporate Planning  
Telephone: (0)3-3525-4707

### **Release of Mometasone Nasal 50 $\mu$ g 「KYORIN」 56sprays, 112sprays**

TOKYO, Japan (August 23, 2019) —Kyorin Rimedio Co., Ltd. (Head office: Kanazawa City, Ishikawa, President: Hiroshi Hashizume), a wholly owned subsidiary of KYORIN Holdings, Inc., announced the release of " Mometasone Nasal 50  $\mu$  g「KYORIN」56sprays, 112 sprays " (Active Ingredient: Mometasone Furoate Hydrate) a therapeutic agent for allergic rhinitis.

This drug is an authorized generic drug for Nasonex, therapeutic agent for allergic rhinitis which are being sold by KYORIN Holdings' subsidiary KYORIN Pharmaceutical Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, President :Shigeru Ogihara).

After this release, in order to meet the needs of medical workers, Kyorin Rimedio Co., Ltd will cooperate with KYORIN Pharmaceutical Co., Ltd. and promote proper use of the product.

Kyorin Group, based on its corporate philosophy of“Contributing to better health”, will continue striving to provide pharmaceuticals that meet the wide-ranging needs of patients and medical professionals.

The sales of the drug is factored in consolidated forecast for the fiscal year ending March 31, 2020 which was announced on May 13, 2019.

#### < Product information >

1. Brand name : Mometasone Nasal 50  $\mu$  g 「KYORIN」 56sprays  
Mometasone Nasal 50  $\mu$  g 「KYORIN」 112sprays
2. Date of Launch in Japan : August 26, 2019
3. NHI Price : 56sprays ¥ 746.10  
112sprays ¥1492.20
4. Manufacturer and seller : KYORIN Rimedio Co., Ltd.
5. Seller : KYORIN Pharmaceutical Co., Ltd.